欧盟批准Jemperli治疗晚期子宫颈癌,显示存活率有所提高。 EU approves Jemperli for advanced endometrial cancer, showing improved survival rates.

欧洲联盟委员会已批准使用Jemperli,一种免疫肿瘤药物,同时对患有晚期或复发性宫内癌的成年病人进行化疗。 The European Commission has approved the use of Jemperli, an immuno-oncology drug, in combination with chemotherapy for adult patients with advanced or recurrent endometrial cancer. 这包括有不匹配修复能力强/微型卫星稳定肿瘤的病人,占病例的75%左右。 This includes patients with mismatch repair proficient/microsatellite stable tumors, which make up about 75% of cases. 根据一项试验,Jemperli加化疗显示,总存活率中位数为44.6个月,而仅化疗就维持了28.2个月,这标志着内脏癌治疗方案有了显著改善。 Based on a trial, Jemperli plus chemotherapy showed a median overall survival of 44.6 months, compared to 28.2 months with chemotherapy alone, marking a significant improvement in treatment options for endometrial cancer.